Stallergenes expands Latin American presence with acquisition of ALERGO PHARMA S.R.L. in Argentina

Stallergenes expands Latin American presence with acquisition of ALERGO PHARMA S.R.L. in Argentina

Stallergenes expands Latin American presence with acquisition of ALERGO PHARMA S.R.L. in Argentina

Antony (France), 21 July 2014 – STALLERGENES, a global healthcare company specialized in the diagnosis and treatment of allergies through allergen immunotherapy-based solutions, announced today the acquisition of the entire share capital of ALERGO PHARMA S.R.L., an Argentinean allergen immunotherapy (AIT) company.

The aim of the acquisition is to combine two complementary dedicated allergen immunotherapy companies, working together to provide a more comprehensive and broader range of diagnosis and treatment solutions to patients suffering from allergic respiratory diseases.

This acquisition establishes STALLERGENES among the top allergen immunotherapy pharmaceutical companies in Latin America further broadening STALLERGENES' geographic presence across the region.

"With its excellent market knowledge, an extensive distribution network and long standing relationships with allergy specialists, ALERGO PHARMA is the leader in the AIT market in Argentina," said Christian Chavy, Chief Executive Officer of STALLERGENES. "This acquisition will significantly enhance STALLERGENES' footprint in Latin America, and is consistent with our long-term strategy and commitment to fast-growing markets." The terms of the transaction are not disclosed.

About respiratory allergies in Argentina
The prevalence of allergic rhinitis in Argentina is estimated at between 20% and 30% of the population.
The Argentinean market offers substantial potential for the development of allergen immunotherapy: 8.5 million people are sensitized and the most prevalent allergen is house dust mites. Each year, 2.3 million people are diagnosed with allergy symptoms.

Today, only 150,000 allergy sufferers are treated with allergen immunotherapy. There is therefore a strong need for innovative standardized allergen immunotherapy treatments.

ABOUT STALLERGENES

STALLERGENES is a global healthcare company specialized in the diagnosis and treatment of allergies. For more than 50 years, it has been continuously expanding the existing frontiers of science in order to provide allergy patients with more effective long lasting therapeutic options. Thanks toits innovation strategy, fueled by investments amounting to around 20% of total annual revenues as well as external partnerships, STALLERGENES is able to provide targeted allergen immunotherapy-based allergy solutions that significantly improve the lives of allergy patients around the world.

STALLERGENES operates in 20 countries and employs over 1,000 people. In 2013, the Company generated total revenues of €248 million, and more than 500,000 patients were treated with STALLERGENES products.

Euronext Paris (Compartment B)

CAC small

ISIN: FR0000065674

Reuters: GEN.PA

Bloomberg: GEN.FP

Additional information is available at http://www.stallergenes.com

ABOUT ALERGO PHARMA S.R.L.

ALERGO PHARMA is a leading developer and provider of allergen immunotherapy products in the Argentinean market. Fully devoted to allergen immunotherapy, it offers a full range of products recognized for the quality of its allergenic extracts and a continuous supply to the allergy market.

ALERGO PHARMA was founded in 1992 and is located in Buenos Aires, Argentina.
Contacts:

Christian Chavy, Chief Executive Officer

Tel. +33 1 55 59 20 04

Investor and analyst relations

Peter Bühler

Chief Financial Officer

Phone: +33 1 55 59 20 95

Email: [email protected]

Investor and press relations agency

FTI Consulting – Analyst and investor contact

Stephan Dubosq

Phone: +33 1 47 03 68 16

Email: [email protected]

Media Relations

Lise Lemonnier

Senior Communication & Public Affairs Director

Phone: + 33 1 55 59 20 96

Email: [email protected]

FTI Consulting – Press contact

Jeanne Bariller

Phone: +33 1 47 03 68 63

Email:[email protected]

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.